STAT3-Targeted Drug Combination for Chemotherapy-Refractory Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chemotherapy treatments for cancers, particularly pancreatic cancer, are ineffective against chemotherapy refractory cancers and often result in severe side effects due to low chemotherapeutic index, with cancer stem cells (CSCs) being inherently resistant, leading to rapid tumor recurrence and metastasis.
Innovation Solution
A drug combination of a therapeutically effective amount of the compound of formula (I), a low dose of gemcitabine, and paclitaxel is administered to inhibit CSCs and enhance chemotherapy sensitivity, targeting the STAT3 pathway to inhibit CSC survival and metastasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy agents are used to kill cancer cells, then tumor regression is achieved, but severe side effects occur due to low chemotherapeutic index
Solution Approach 1:
The invention segments the cancer cell population into two distinct targets: bulk tumor cells and cancer stem cells (CSCs). By using a combination of conventional chemotherapy (to target bulk cells) and STAT3 inhibitors (to target CSCs), the therapy addresses different segments of the cancer ecosystem with specialized agents, thereby improving overall efficacy while managing toxicity through targeted action on resistant subpopulations
Solution Approach 2:
The invention creates a composite therapeutic strategy by combining conventional chemotherapy agents with STAT3 pathway inhibitors. This composite approach leverages the strengths of both treatment modalities: chemotherapy provides immediate cytotoxic activity against bulk cells, while STAT3 inhibition provides sustained suppression of CSCs, achieving synergistic effects that overcome the limitations of single-agent therapy
2Productivity
If high dose chemotherapy is administered to achieve effective cancer cell killing, then tumor regression is improved, but normal cell damage increases
Solution Approach 1:
The invention applies local quality by directing different therapeutic mechanisms to different cellular targets within the tumor ecosystem. Conventional chemotherapy is optimized for bulk tumor cells, while STAT3 inhibitors are specifically directed at CSCs. This localized targeting allows each agent to operate at optimal effectiveness without requiring excessive doses that would harm normal tissues, thereby improving cancer cell killing efficiency while reducing normal cell damage
3Reliability
If conventional chemotherapy is used to treat cancer, then initial tumor response is achieved, but rapid relapse occurs due to CSC resistance
Solution Approach 1:
The invention implements preliminary action by targeting CSCs before they can cause relapse. By incorporating STAT3 inhibitors that specifically suppress CSC survival and self-renewal capabilities into the initial treatment regimen, the therapy prevents the reservoir of disease-seeding cells from forming, thereby extending disease freedom beyond the initial tumor response
4Reliability
If cancer stem cells are targeted to prevent recurrence, then relapse is reduced, but treatment complexity increases
Solution Approach 1:
The invention uses STAT3 inhibitors as intermediary agents that bridge conventional chemotherapy and CSC targeting. These inhibitors act as mediators that enhance the efficacy of conventional chemotherapy while simultaneously suppressing CSCs, thereby preventing recurrence without requiring entirely separate treatment protocols for bulk cells and stem cells
Data Source
AI summary
The use of a pharmaceutical composition in treating cancer in a subject comprising a therapeutically effective amount of a compound of formula (I), a therapeutically effective amount of paclitaxel and a low dose of gemcitabine, and a kit included above composition thereof.